Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
Patrick B MarkRichard PapworthNitish RamparsadLaurie A TomlinsonSimon SawhneyCorri BlackAlex McConnachieColin McCowanPublished in: British journal of clinical pharmacology (2020)
In patients prescribed ACEi/ARB, the highest risk of AKI is associated with conditions which are considered strong evidence-based indications for their prescription. Socio-economic status is an under-reported risk factor for AKI with these agents. Strategies targeted at prevention of AKI may be of benefit, such as enhanced awareness based on higher risk comorbidities.